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Introduction
Metastatic lesions over the penis and anterior urethra
are rare, and most commonly develop from pelvic or-
gans such as the prostate, urinary bladder and colon, or,
in some cases, from advanced lung and kidney malig-
nancies. Despite the proximity, prostate cancer seldom
metastasizes to the urethra. Most reported urethral
metastases from prostate cancer are related to previous
surgeries or disease progression.1,2 Newly diagnosed
prostate cancer presenting as a urethral tumor has never
been reported.
Case Report
A 77-year-old man presented with voiding straining and
a bifurcated voiding stream for 3 months. He had a his-
tory of cerebral vascular accidents 6 months before the
above symptoms and had undergone a urethral cathe-
terization at that time. His prostate-specific antigen
(PSA) level was 5.02ng/mL. Digital rectal examination
disclosed stony hard tumors at both lobes of the pro-
state. Cystoscopy revealed a tumor lesion at the penile
urethra, 8 cm from the meatus and 2 cm distal to the
bulbous urethra. The urethral lumen was partially ob-
structed (Figure 1). Transurethral resection of the tu-
mor found metastatic adenocarcinoma of the prostate;
the Gleason score was 4+4=8. Transrectal ultrasound-
guided biopsy of the prostate revealed adenocarcinoma
over both lobes of the prostate; the Gleason score was
4 + 4 = 8. Computed tomography showed enlarged ly-
mph nodes around the para-aortic space and the pelvic
cavity. A bone scan showed metastatic lesions at the
sacroiliac joint, right ischium and left acetabulum.
Magnetic resonance imaging demonstrated a linear
lesion extending from the prostate gland to the corpus
spongiosum and the corpus cavernosum (Figure 2).
The patient received hormone therapy with the anti-
androgen cyproterone acetate. The serum PSA levels de-
creased to a nadir of less than 0.01 ng/mL 8 months
later and then rapidly rose to 2.24 ng/mL in the 15th
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month. PSA levels continued to increase after discontin-
uing cyproterone acetate and were resistant to luteinizing
hormone-releasing hormone agonist therapy. A bone
scan revealed increasing uptake in the metastatic area.
Cystoscopy showed diffuse tumor seeding in the prosta-
tic, bulbous and penile urethra with partial obstruction.
The patient then received chemotherapy with docetaxel
75mg/m2 in the 17th month after diagnosis. PSA levels
continued to rise to 14.53 ng/mL in the 20th month.
The patient had another episode of cerebral infarct dur-
ing the 23rd month and died of pneumonia in the 25th
month.
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Figure 1. Cystoscopy shows a urethral tumor located 8 cm from
the urethra meatus with partial obstruction.
Figure 2. Multiple linear nodular lesions (arrows) are found in the
left side of the corpus spongiosum and corpus cavernosum of the
penis, with relatively heterogeneous signal intensity on T2-weighted
imaging, sagittal view, which is compatible with prostate cancer
metastasis.
Discussion
Metastatic routes of prostate cancer to the corpus caver-
nosum or the anterior urethra have been postulated,
including direct extension, implantation by instrumen-
tation, lymphatic spread, and dissemination through the
blood stream.3 It is not uncommon for advanced pro-
state cancer patients to receive transurethral surgery to
maintain urinary tract patency.4 Malignant implantation
by instrumentation may develop after the procedure.
There have been 12 cases of metastatic prostate cancer
to the anterior urethra have been previously reported.2,5
Of these cases, 11 had a history of previous instrumenta-
tion and prostate resection. All the tumors of these cases
were solitary and did not involve the corpus cavernosa.
Direct extension of a tumor to the corpus caver-
nosum or the spongiosum may cause stiffness of the
penis or urethral stricture. Intraluminal tumor seeding is
seldom seen in this type of metastasis. In this situa-
tion, the tumor burden is usually large.
Another possible mechanism, retrograde venous
spread, has been reported as the most frequent mecha-
nism accounting for metastasis to the penile corpora
cavernosa caused by extensive intercommunications
between the deep dorsal vein of the penis and the pu-
dendal, pelvic, and prostatic venous plexuses.6
In our patient report, we had a unique finding in
which the tumor had extended to the corpus caverno-
sum and corpus spongiosum, and sprouted. As shown
by magnetic resonance imaging, the tumor burden was
not large and the prostate capsule margin did not show
locally extensive behavior. The mechanisms of metas-
tasis are likely to be venous spreading and intraurethral
growth.
The treatment options for this type of tumor include
local resection, radiation therapy and hormone therapy.
Green et al reported good control using combined radi-
ation and hormone therapy for a patient with recur-
rence of ductal carcinoma.2 In their case, only urethral
mucosa was involved and the follow-up period was
short. We performed hormone therapy instead of local
radiotherapy because the patient had systemic metasta-
tic disease. We performed local resection of the urethral
tumor combined with anti-androgen treatment for the
patient. Biochemical control was achieved in the initial
15 months but the disease rapidly progressed to a
hormone-refractory status and was out of control even
after we replaced the therapy with a luteinizing hormone-
releasing hormone agonist and docetaxel.
Prognosis of patients with metastatic prostatic
cancer to the penis is very poor. An evaluation of 
25 patients with penile metastasis from prostatic cancer
in Japan found that 11 patients (41%) died of cancer
within 6 months of the diagnosis.7 The 25-month
survival of our patient was also shorter than that in
the Taiwanese series reported by Chen et al with
metastatic prostate cancer (survival range of 33–45
months).8
We have presented a rare case of prostate cancer with
metastases to the corpus cavernosum and the corpus
spongiosum with urethral tumor sprouting. Elderly
men should be aware of the danger of silent prostate
cancer and seek medical advice or treatment before the
disease advances.
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